HomeSNY • NASDAQ
add
Sanofi SA
Previous close
$52.88
Day range
$53.10 - $53.77
Year range
$45.00 - $58.97
Market cap
134.75B USD
Avg Volume
1.91M
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 14.16B | 11.49% |
Operating expense | 5.99B | 11.39% |
Net income | 2.82B | 11.49% |
Net profit margin | 19.88 | -0.05% |
Earnings per share | 1.54 | 14.37% |
EBITDA | 4.91B | 15.96% |
Effective tax rate | 20.58% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 6.80B | -14.99% |
Total assets | — | — |
Total liabilities | — | — |
Total equity | 73.00B | — |
Shares outstanding | 1.25B | — |
Price to book | 0.91 | — |
Return on assets | — | — |
Return on capital | 10.54% | — |
Cash Flow
Net change in cash
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 2.82B | 11.49% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Wikipedia
CEO
Founded
1973
Headquarters
Website
Employees
86,088
